Literature DB >> 6174196

Peritoneovenous shunt for palliation of malignant ascites.

R Qazi, E D Savlov.   

Abstract

Forty patients with malignant ascites refractory to conventional medical management had peritoneovenous shunt for palliation. The shunt provided effective palliation in 28 with decrease in weight, abdominal girth, number of paracenteses required and increase in urine output. These patients also had improvement in strength, appetite and ambulation. Complications such as hemodilution, volume overload, and sepsis do not contraindicate surgery. In 12 patients with high ascitic fluid protein content (4.5 g/liter) and a large number of malignant cells, loculated ascites and prior severe renal and cardiac disease, the shunt did not provide palliation. Peritoneovenous shunt appears to provide effective palliation in carefully selected patients with refractory malignant ascites.

Entities:  

Mesh:

Year:  1982        PMID: 6174196     DOI: 10.1002/1097-0142(19820201)49:3<600::aid-cncr2820490333>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Peritoneovenous shunt for pancreatic ascites.

Authors:  B De Waele; P Van der Spek; G Devis
Journal:  Dig Dis Sci       Date:  1987-05       Impact factor: 3.199

2.  Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts.

Authors:  D Tarin; J E Price; M G Kettlewell; R G Souter; A C Vass; B Crossley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-10

3.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

4.  Peritoneovenous shunts in malignant ascites.

Authors:  J H Helzberg; N J Greenberger
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Peritoneovenous shunts for palliation of the patient with malignant ascites.

Authors:  D L Schumacher; T J Saclarides; E D Staren
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

6.  Palliation of malignant ascites by the Denver peritoneovenous shunt.

Authors:  R Downing; J Black; C W Windsor
Journal:  Ann R Coll Surg Engl       Date:  1984-09       Impact factor: 1.891

7.  Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascites.

Authors:  Hiroyuki Tokue; Yoshito Takeuchi; Yasuaki Arai; Keitaro Sofue; Noriaki Sakamoto; Yoshito Tsushima; Keigo Endo
Journal:  World J Surg Oncol       Date:  2011-07-21       Impact factor: 2.754

Review 8.  Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Clin Pharmacol       Date:  2013-10-03

9.  Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Int J Womens Health       Date:  2012-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.